Stricter Regulation in the United States of Direct-to-Consumer Drug Advertising: Better, but Not Enough

In September 2025, President Donald J. Trump directed the Department of Health and Human Services and the Food and Drug Administration to strengthen enforcement of prescription drug advertising regulations. In response, plans were announced to close digital loopholes in direct-to-consumer advertising, pursue regulatory violations, and eliminate the 1997 "adequate provision," which permits advertisements to omit key safety information. Although these reforms aim to promote "radical transparency," their impact on prescribing patterns is uncertain. Direct-to-consumer advertising is designed to elicit a strong positive emotional response that affects one's ability to properly weigh risk. Even if direct-to-consumer advertisements are required to disclose more information regarding potential risks, the emotional response elicited will still positively influence demand. This is not speculation: there is ample evidence before the implementation of the 1997 adequate provision showing that pharmaceutical advertising influenced prescribing behavior. Accordingly, it is unlikely that pending regulatory and enforcement changes will meaningfully reduce overdiagnosis, overtreatment, or health care spending. However, given the current momentum to confront these problems, public health scholars should seize the opportunity and advance evidence-based policy solutions. (Am J Public Health. 2026;116(9): 1352-1357. https://doi.org/10.2105/AJPH.2026.308469).